3-Methyl-PCPy
Chemical compound
- None
- CA: Schedule I
- DE: NpSG (Industrial and scientific use only)
- UK: Class B
- 1-[1-(3-methylphenyl)cyclohexyl]pyrrolidine
- 1622348-63-3 Y
- 137332188
- FS9Z5C7CQ5
- DTXSID201337066
- Interactive image
- CC1=CC(=CC=C1)C2(CCCCC2)N3CCCC3
InChI
- InChI=1S/C17H25N/c1-15-8-7-9-16(14-15)17(10-3-2-4-11-17)18-12-5-6-13-18/h7-9,14H,2-6,10-13H2,1H3
- Key:JZVMREFYFTZXGN-UHFFFAOYSA-N
3-Methyl-PCPy (3-Me-PCPy) is an arylcyclohexylamine derivative with an unusual spectrum of pharmacological effects, acting as both a potent NMDA antagonist and also a triple reuptake inhibitor which inhibits reuptake of all three monoamine neurotransmitters serotonin, dopamine and noradrenaline. It also acts as a high affinity sigma receptor ligand, selective for the σ2 subtype. It produces both stimulant and dissociative effects in animal behavioural studies.[1][2][3]
Legal Status
3-Methyl-PCPy is covered by drug analogue laws in various jurisdictions (UK, Germany, Japan, Australia etc.) as a generic arylcyclohexylamine derivative, and a structural isomer of phencyclidine.
See also
References
- ^ Wallach J, De Paoli G, Adejare A, Brandt SD (2014). "Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues". Drug Testing and Analysis. 6 (7–8): 633–50. doi:10.1002/dta.1468. PMID 23554350.
- ^ Morris H, Wallach J (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis. 6 (7–8): 614–32. doi:10.1002/dta.1620. PMID 24678061.
- ^ Wallach J, Brandt SD (2018). "Phencyclidine-Based New Psychoactive Substances". New Psychoactive Substances. Handbook of Experimental Pharmacology. Vol. 252. pp. 261–303. doi:10.1007/164_2018_124. ISBN 978-3-030-10560-0. PMID 30105474.
- v
- t
- e